Janssen Pharmaceutica (Johnson & Johnson Innovative Medicine) — Cyborg Score 8/10

Strong
Pharmaceutical Manufacturing & Drug Development

Strategic Profile

Janssen serves as a Center of Excellence in small molecule discovery and development with world-class capabilities in Discovery, Chemical Development, Clinical Development, and Regulatory functions. The company has delivered 20 new medicines since 2011 and has redefined treatment paradigms for many serious diseases. Its strategic advantage lies in its integrated campus model combining research, manufacturing, and clinical trial infrastructure—critical to J&J's pharma strategy.

Cyborg Score Rationale

In 2020, Janssen in Belgium invested €2.2 billion in R&D. The company combines high R&D spend with proven drug discovery track record, scale manufacturing capabilities, and integration into J&J's global operations. As a private subsidiary, it lacks public market pressures but benefits from parent-company resources.

Top Insights

  • Geel manufacturing site produces approximately two-thirds of worldwide chemical production for J&J's pharmaceutical sector.
  • Campus has been instrumental in discovering major tuberculosis, HIV/AIDS, cancer and neurological drugs; first FDA-approved TB drug in 40 years was discovered here.
  • Over 5,000 employees (70+ nationalities) including 2,458 researchers operate across seven Belgian sites.
  • First JLABS in Europe established in 2015 to support life science startups and ecosystem innovation.

Named Competitors

  • Pharma Division — Oncology and immunology competitor in drug discovery and development
  • Pharma Division — Rival in neuroscience, oncology, and immunology therapeutics
  • Pharma Division — Competitor in oncology and infectious disease pharma
  • Pharma Division — Competitor in vaccines and specialty pharma

Recent Developments

  • (2020) Invested €2.2 billion in R&D for innovation and technologies across unmet medical needs
  • (2021) Recognized as Most Attractive Private Employer per Randstad Employer Brand Study
  • (2024) Continues leadership in clinical trials and pharmaceutical innovation hub operations

Open the full interactive Janssen Pharmaceutica (Johnson & Johnson Innovative Medicine) report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →